 Aptose Biosciences Inc NASDAQ: APTO highlighted data from its luxeptinib currently in two Phase 1 ab trials - one in relapsed or refractory acute myeloid leukemia AML and another in relapsed or refractory B cell malignancies. In Relapsed or Refractory AML or High-Risk MDS trial, APTO-253 has been well-tolerated in the patients treated at 20, 40, 66, 100, and 150 mgm2 over multiple cycles supporting continued dose escalation. 